Boston, MA, July 15, 2025 — Alloy Therapeutics Inc. (“Alloy”), a biotechnology ecosystem company dedicated to democratizing access to cutting-edge drug discovery technologies, announced today that it has entered a Memorandum of Understanding (MoU) with the Republic of Serbia’s BIO4 Campus. This collaboration aims to advance the global bioeconomy by expanding access to Alloy’s discovery platforms and accelerating the creation of biotech startups in emerging innovation ecosystems.
As part of Alloy’s Sovereign Innovation Business Unit, Alloy will work with Serbia to help cultivate a vibrant, interconnected biotechnology ecosystem that supports the country’s long-term national goals in areas such as drug discovery and biomanufacturing. Drawing on its platform technologies and business-building expertise, Alloy will help launch and scale new ventures in the country, empowering local scientists and entrepreneurs while fostering cross-border innovation that contributes to health and economic resilience across Europe.
Alloy will engage with Serbia to design and implement programs that provide startups and researchers with access to advanced drug discovery capabilities, scientific expertise, as well as manufacturing and business infrastructure. Participating ventures will be supported across the full R&D lifecycle, from idea to proof-of-concept and beyond, helping accelerate the development of new therapies and biotechnologies. In Serbia, this work will be anchored at the BIO4 Campus, a flagship life sciences hub scheduled to open in 2027 with more than 1,000 PhD scientists from 16 academic institutions.
“This partnership is a strong endorsement of Serbia’s ambition to become a leader in biotechnology,” said Smiljana Krivokuća, CEO of the BIO4 Campus. “By working with Alloy to empower our biologics manufacturing ability, scientists and entrepreneurs, we are creating a sustainable pipeline of innovation and a globally competitive life sciences sector rooted in Serbia’s BIO4 Campus.”
This agreement reflects Alloy’s ongoing commitment to reinvesting in the scientific ecosystem and building long-term, high-impact partnerships with governments, academia, and industry.
“At Alloy, we believe citizens anywhere in the world should be able to access the medicine they need,” said Errik Anderson, Founder & CEO of Alloy Therapeutics. “We’re grateful to partner with those who share our commitment to advancing science and expanding access. This collaboration reflects that alignment and supports the growth of globally connected, entrepreneurial biopharma ecosystems.”
About Alloy Therapeutics
Alloy Therapeutics is a biotechnology ecosystem company empowering the global scientific community to make better medicines together. Through a community of partners across academia, biotech, and the largest biopharma, Alloy democratizes access to pre-competitive tools, technologies, services, and company creation capabilities that are foundational for discovering and developing therapeutic biologics across six modalities: antibodies, bispecifics, TCRs, genetic medicines, cell therapies, and drug delivery. Partners may access all current and future technologies through a discovery service relationship or for a flat fee through Alloy’s Innovation Subscriptions offering. As a reflection of Alloy’s relentless commitment to the scientific community, Alloy reinvests 100% of its revenue in innovation and access to innovation.
Join the Alloy Therapeutics community by visiting alloytx.com and following Alloy on LinkedIn.
Contacts
Chris Bedi
